Mitabor Disper (Mirtazapine)

Mirtazapine, the active ingredient in Mitabor Disper, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mitabor Disper as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on central neurotransmitter pathways to alleviate depressive conditions. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depression with insomnia: helps restore sleep quality while treating depressive mood. - Depression with anxiety features: may lessen anxiety symptoms alongside mood improvement.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Seizures - Suicidal thoughts or behavior, especially early in treatment - Hepatic dysfunction or jaundice - Unexplained fever or rash

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: adjust use in severe liver impairment. - Monitor weight: significant weight gain may occur. - Evaluate for suicidal ideation: especially during the first weeks of treatment. - Use caution in patients with cardiovascular disease: may cause orthostatic hypotension. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise mirtazapine plasma levels. - Central nervous system depressants (alcohol, benzodiazepines): enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine): altered metabolism may occur. - Anticholinergic agents: additive dry‑mouth effect. - Other serotonergic drugs (SSRIs, SNRIs): potential for serotonin syndrome.